Nogo-66 receptor antagonist peptide (NEP1-40) administration promotes functional recovery and axonal growth after lateral funiculus injury in the adult rat

Neurorehabil Neural Repair. 2008 May-Jun;22(3):262-78. doi: 10.1177/1545968307308550. Epub 2007 Nov 30.

Abstract

Objective: The myelin protein Nogo inhibits axon regeneration by binding to its receptor (NgR) on axons. Intrathecal delivery of an NgR antagonist (NEP1-40) promotes growth of injured corticospinal axons and recovery of motor function following a dorsal hemisection. The authors used a similar design to examine recovery and repair after a lesion that interrupts the rubrospinal tract (RST).

Methods: Rats received a lateral funiculotomy at C4 and NEP1-40 or vehicle was delivered to the cervical spinal cord for 4 weeks. Outcome measures included motor and sensory tests and immunohistochemistry.

Results: Gait analysis showed recovery in the NEP1-40-treated group compared to operated controls, and a test of forelimb usage also showed a beneficial effect. The density of labeled RST axons increased ipsilaterally in the NEP1-40 group in the lateral funiculus rostral to the lesion and contralaterally in both gray and white matter. Thus, rubrospinal axons exhibited diminished dieback and/or growth up to the lesion site. This was accompanied by greater density of 5HT and calcitonin gene-related peptide axons adjacent to and into the lesion/matrix site in the NEP1-40 group.

Conclusions: NgR blockade after RST injury is associated with axonal growth and/or diminished dieback of severed RST axons up to but not into or beyond the lesion/matrix site, and growth of serotonergic and dorsal root axons adjacent to and into the lesion/matrix site. NgR blockade also supported partial recovery of function. The authors' results indicate that severed rubrospinal axons respond to NEP1-40 treatment but less robustly than corticospinal, raphe-spinal, or dorsal root axons.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Behavior, Animal / drug effects
  • Denervation
  • Efferent Pathways / drug effects
  • Efferent Pathways / metabolism
  • Efferent Pathways / physiopathology
  • Female
  • GPI-Linked Proteins
  • Growth Cones / drug effects*
  • Growth Cones / metabolism
  • Myelin Proteins / antagonists & inhibitors*
  • Myelin Proteins / metabolism
  • Myelin Proteins / pharmacology*
  • Myelin Proteins / therapeutic use
  • Nerve Regeneration / drug effects*
  • Nerve Regeneration / physiology
  • Neuronal Plasticity / drug effects
  • Neuronal Plasticity / physiology
  • Nogo Receptor 1
  • Peptide Fragments / pharmacology*
  • Peptide Fragments / therapeutic use
  • Pyramidal Tracts / drug effects
  • Pyramidal Tracts / metabolism
  • Pyramidal Tracts / physiopathology
  • Raphe Nuclei / drug effects
  • Raphe Nuclei / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Cell Surface / antagonists & inhibitors*
  • Receptors, Cell Surface / metabolism
  • Recovery of Function / drug effects
  • Recovery of Function / physiology
  • Red Nucleus / drug effects
  • Red Nucleus / metabolism
  • Spinal Cord Injuries / drug therapy*
  • Spinal Cord Injuries / metabolism
  • Spinal Cord Injuries / physiopathology
  • Spinal Nerve Roots / drug effects
  • Spinal Nerve Roots / metabolism
  • Treatment Outcome
  • Wallerian Degeneration / drug therapy
  • Wallerian Degeneration / metabolism
  • Wallerian Degeneration / physiopathology

Substances

  • GPI-Linked Proteins
  • Myelin Proteins
  • NEP1-40 protein, human
  • Nogo Receptor 1
  • Peptide Fragments
  • Receptors, Cell Surface
  • Rtn4r protein, rat